World Health Organization Issues Warning Over Acute Scarcity of Weight-Loss Injections
Fewer than a tenth of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it publishes its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging broader and more equitable access to GLP-1 medication.
Based on estimates, over two billion will be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a chronic disease that can be treated with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key barriers to universal availability to the jabs that can help people shift substantial body mass, notes the organization.
Skinny Jab Shortage
Even in the current most favorable outlook, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, according to the health organization.
The advice urges countries and companies to widen availability, by approaches like voluntary licensing.
A patent on semaglutide – the core component of a leading brand – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Drugs Function
These medications imitate a body's own hormone to delay gastric emptying, suppress the appetite and increase satiety so users reduce food intake.
Patients commonly start to lose weight in the initial weeks of beginning the regular doses.
Research indicates patients may see weight return within a year of discontinuing the drug, because their typical food cravings resume.
Being overweight or obese elevates your chance for experiencing health problems, such as diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.
